MONTREAL, May 16 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE),a specialty bio-therapeutics company developing high-value human proteins forcommercialization, announced today that its Chairman of the Board and ChiefExecutive Officer, Joseph Galli, will present at the upcoming Rodman & Renshaw5th Annual Global Healthcare Conference on Tuesday, May 20, 2008 in the ZephyrRoom at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco, beginning at1:40 p.m Central European Summer Time (7:40 a.m. Eastern Daylight Time).
Rodman & Renshaw will webcast the audio portion of the presentation andpost the associated slides via its website at www.rodmanandrenshaw.com, hostedby Wall Street Webcasting. To access the live broadcast via internet inlisten-only mode, or the subsequently archived recording, simply cut and pastethe following link directly into your web browser:http://www.wsw.com/webcast/rrshq13/hae.cn
Please visit the site at least five minutes prior to start time forinstructions.
About Rodman & Renshaw's Annual Global Healthcare Conference
The conference will include presentations by over 200 companies, as wellas experts from the medical, scientific and investment communities. Detailsregarding the conference can be obtained at www.rodmanandrenshaw.com
Haemacure also announced today the resignation of Mr. Neil Weiner from theBoard of Directors of the Company. "On behalf of the Board and managementteam, I wish to thank Neil for his tremendous contribution and dedication toHaemacure" commented Joseph Galli, Chairman and CEO of Haemacure.
Haemacure Corporation is a specialty biotherapeutics company developinghigh-value human plasma-derived protein products for commercialization.Haemacure's research and development effort is driven by its proprietaryplasma protein extraction technology to develop next-generation products,including surgical hemostats. Haemacure's lead product candidate,Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/PhaseIII clinical trials during the first quarter of 2009. Haemacure's secondproduct candidate is thrombin, a component of its fibrin sealant, now inpreclinical stage. Follow-on development will focus on surgical hemostats,wound healing, adhesion prevention, regenerative medecine, drug delivery andcombination with biomaterials. Haemacure has discovered eleven additionalspecialty proteins and enzymes in one if its two plasma fractions and seeks toadvance these proteins and enzymes through partnerships with pharmaceuticaland biotechnology companies. Haemacure operates offices in Sarasota, Floridathrough a wholly-owned subsidiary. The Corporation is traded under stocksymbol HAE on the TSX.
SOURCE HAEMACURE CORPORATION